Hosted by Sarah Mitchell & James Carter
Downloads
More from: Heart Failure Deep Dive Series

Sarah Mitchell & James Carter

Sarah Mitchell & James Carter

Sarah Mitchell & James Carter
- Obesity is causal in HFpEF via epicardial fat - directly drives cardiac inflammation and fibrosis
- STEP-HFpEF: semaglutide improved KCCQ +16 pts, 6MWD +21m, weight -13.3% vs placebo; Class IIa ESC recommendation
- SGLT2 inhibitors and GLP-1 agonists are mechanistically complementary in HFpEF
- Metabolic cardiomyopathy paradigm: treating the systemic environment, not just the haemodynamics
Cite This Article
Team TLSFE. Semaglutide for obese heart failure patients. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/cardiology/heart-failure/research/semaglutide-for-obese-heart-failure-patients.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Podcast Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
[1] Kosiborod MN et al. STEP-HFpEF. N Engl J Med. 2023;389:1069-1084
[2] Kosiborod MN et al. STEP-HFpEF-DM. N Engl J Med. 2023;389:1085-1098
[3] Lehrke M et al. SELECT. N Engl J Med. 2023;389:2221-2232
[4] Borlaug BA et al. Heart Failure. 2023;11:1339-1356

